A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area

被引:27
作者
Dow, Geoffrey S. [1 ]
McCarthy, William F. [1 ]
Reid, Mark [2 ]
Smith, Bryan [1 ]
Tang, Douglas [1 ]
Shanks, G. Dennis [3 ]
机构
[1] US Army Med Mat Dev Act, Ft Detrick, MD 21702 USA
[2] Clin Network Serv, Toowong, Qld 4066, Australia
[3] Australian Army Malaria Inst, Enoggera, Qld 4051, Australia
关键词
PLASMODIUM-VIVAX; DOUBLE-BLIND; PRIMAQUINE; TOLERABILITY; REGIMENS; TRIAL;
D O I
10.1186/1475-2875-13-49
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: In 2000/2001, the Australian Defense Forces (ADF), in collaboration with SmithKline Beecham and the United States Army, conducted a field trial to evaluate the safety, tolerability and efficacy of tafenoquine and mefloquine/primaquine for the prophylaxis of malaria amongst non-immune Australian soldiers deployed to East Timor (now called Timor Leste) for peacekeeping operations. The lack of a concurrent placebo control arm prevented an internal estimate of the malaria attack rate and so the protective efficacy of the study regimens was not determined at the time. Methods: In a retrospective analysis of the trial results, the all species malaria attack rate was estimated for the prophylactic phase of the study which was defined as the period between administration of the first prophylactic dose and the first dose of post-deployment medication. First, the Plasmodium vivax attack rate was estimated during the prophylactic phase of the deployment by adjusting the observed P. vivax relapse rate during post-deployment to account for the known anti-relapse efficacies (or effectiveness) of the study medications (determined from prior studies). The all species malaria attack rate (P. vivax and Plasmodium falciparum) was then determined by adjusting the P. vivax attack rate based on the ratio of P. falciparum to P. vivax observed during prior ADF deployments to Timor Leste. This estimated all species malaria attack rate was then used as the `constant estimated attack rate' in the calculation of the protective efficacy of tafenoquine and mefloquine during the prophylactic phase of the deployment. Results: The estimated attack rate during the prophylactic phase of the study was determined to be 7.88%. The protective efficacies of tafenoquine and mefloquine, with corresponding 95% confidence intervals (95% CI), were determined to be 100% (93%-100%) and 100% (79%-100%) respectively. Conclusions: The protective efficacy of tafenoquine (200 mg per day for three days, followed by weekly 200 mg maintenance doses) is similar to that of the weekly standard of care (mefloquine, 250 mg).
引用
收藏
页数:13
相关论文
共 27 条
[1]  
[Anonymous], INTR NAT NOT DIS SUR
[2]   TREATMENT OF CHLOROQUINE-RESISTANT PLASMODIUM-VIVAX WITH CHLOROQUINE AND PRIMAQUINE OR HALOFANTRINE [J].
BAIRD, JK ;
BASRI, H ;
SUBIANTO, B ;
FRYAUFF, DJ ;
MCELROY, PD ;
LEKSANA, B ;
RICHIE, TL ;
MASBAR, S ;
WIGNALL, FS ;
HOFFMAN, SL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) :1678-1682
[3]   Rainy-season prevalence of malaria in Bobonaro district, East Timor [J].
Bragonier, R ;
Reyburn, H ;
Nasveld, P ;
Edstein, M ;
Auliffe, A .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2002, 96 (07) :739-743
[4]   Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects [J].
Charles, Bruce G. ;
Miller, Ann K. ;
Nasveld, Peter E. ;
Reid, Mark G. ;
Harris, Ivor E. ;
Edstein, Michael D. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2709-2715
[5]   Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) [J].
Dow, Geoffrey S. ;
Gettayacamin, Montip ;
Hansukjariya, Pranee ;
Imerbsin, Rawiwan ;
Komcharoen, Srawuth ;
Sattabongkot, Jetsumon ;
Kyle, Dennis ;
Milhous, Wilbur ;
Cozens, Simon ;
Kenworthy, David ;
Miller, Anne ;
Veazey, Jim ;
Ohrt, Colin .
MALARIA JOURNAL, 2011, 10
[6]  
Dow Geoffrey S, 2008, Ther Clin Risk Manag, V4, P803
[7]   Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis [J].
Edstein, MD ;
Kocisko, DA ;
Walsh, DS ;
Eamsila, C ;
Charles, BG ;
Rieckmann, KH .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (12) :1654-1658
[8]   The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific [J].
Elmes, N. J. ;
Nasveld, P. E. ;
Kitchener, S. J. ;
Kocisko, D. A. ;
Edstein, M. D. .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2008, 102 (11) :1095-1101
[9]  
FDA, 2007, GUID IND MA IN PRESS
[10]   A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum [J].
Hale, BR ;
Owusu-Agyei, S ;
Fryauff, DJ ;
Koram, KA ;
Adjuik, M ;
Oduro, AR ;
Prescott, WR ;
Baird, JK ;
Nkrumah, F ;
Ritchie, TL ;
Franke, ED ;
Binka, FN ;
Horton, J ;
Hoffman, SL .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :541-549